Table 2.
Correlations of PSAT1 expression with the clinicopathological features of patients in the TCGA LGG cohort.
| Clinicopathological Feature | N | PSAT1 Expression, N (%) | p | |
|---|---|---|---|---|
| 520 | Low, n = 260 (50.0) | High, n = 260 (50.0) | ||
| Overall survival indicator | *** 0.000286 | |||
| 1 (dead) | 132 | 84 (63.6) | 48 (36.4) | |
| 0 (alive) | 388 | 176 (45.4) | 212 (54.6) | |
| Chromosome 1p19q status | * 0.011473 | |||
| Codeleted | 169 | 98 (58.0) | 71 (42.0) | |
| Not-codeleted | 351 | 162 (46.2) | 189 (53.8) | |
| Age | ** 0.001172 | |||
| >40 | 265 | 151 (57.0) | 114 (43.0) | |
| ≤40 | 255 | 109 (42.7) | 146 (57.3) | |
| WHO histological Grade | *** 2.246 × 10−7 | |||
| Grade III | 269 | 164 (61.0) | 105 (39.0) | |
| Grade II | 251 | 96 (38.2) | 155 (61.8) | |
| IDH1 status | *** 0.000149 | |||
| Wild-type | 116 | 76 (65.5) | 40 (34.5) | |
| Mutant | 404 | 184 (45.5) | 220 (54.5) | |
| TP53 status | *** 0.000055 | |||
| Wild-type | 262 | 154 (58.8) | 108 (41.2) | |
| Mutant | 258 | 106 (41.1) | 152 (58.9) | |
| ATRX status | *** 1.713 × 10−7 | |||
| Wild-type | 320 | 189 (59.1) | 131 (40.9) | |
| Mutant | 200 | 71 (35.5) | 129 (64.5) | |
| CIC status | 0.053261 | |||
| Mutant | 110 | 64 (58.2) | 46 (41.8) | |
| Wild-type | 410 | 196 (47.8) | 214 (52.2) | |
| FUBP1 status | ** 0.006392 | |||
| Mutant | 48 | 33 (68.8) | 15 (31.3) | |
| Wild-type | 472 | 227 (48.1) | 245 (51.9) | |
| TERT expression | *** 0.000026 | |||
| High | 260 | 154 (59.2) | 106 (40.8) | |
| Low | 260 | 106 (40.8) | 154 (59.2) | |
The symbols *, ** and *** denote p < 0.05, p < 0.01 and p < 0.001, respectively.